NEW YORK, Jan. 6, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced
that the Company executed a Patent License Agreement for technology
that covers the use of psilocybin for cancer applications.
The technology is covered by four patent applications already on
file with the United States Patent and Trademark Office.
Psilocybin is a naturally occurring psychedelic
compound. Research has shown psilocybin to have potential to
treat a range of psychiatric and behavioral disorders, notably,
cancer-related depression and anxiety. The use of psilocybin
to treat cancer patients is a growing field. Studies by such
notable institutions as Johns Hopkins
and NYU Grossman School of Medicine found that one-time,
single-dose treatments of psilocybin, combined with psychotherapy,
appears to be associated with significant improvements in emotional
distress in people with cancer and that these effects persisted
nearly five years after the drug was administered.
Mr. Anthony Hayes, CEO of AIkido,
stated, "We are excited to explore this aspect of cancer
treatment. Our license covers the use of psilocybin to treat
both cancer and cancer side-effects and we believe this to be an
expanding area for treatment."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of
Texas at Austin and Wake
Forest University. Our diverse pipeline of therapeutics includes
therapies for pancreatic cancer, acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-executes-licensing-agreement-for-psilocybin-for-cancer-applications-301201491.html
SOURCE AIkido Pharma Inc.